Janssen returns Astellas's JAK inhibitor
This article was originally published in Scrip
Executive Summary
Johnson & Johnson company Janssen Biotech has returned rights to Astellas Pharma's investigational oral Janus Kinase (JAK) inhibitor, ASP015K, effective 15 January 2015. The US firm has terminated a license agreement that was signed in 2012.